Neogenomics (NEO) EBIAT (2016 - 2025)
Neogenomics (NEO) has disclosed EBIAT for 16 consecutive years, with -$9.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 35.52% year-over-year to -$9.9 million, compared with a TTM value of -$108.0 million through Dec 2025, down 37.22%, and an annual FY2025 reading of -$108.0 million, down 37.22% over the prior year.
- EBIAT was -$9.9 million for Q4 2025 at Neogenomics, up from -$27.1 million in the prior quarter.
- Across five years, EBIAT topped out at $75.9 million in Q2 2021 and bottomed at -$49.4 million in Q1 2022.
- Average EBIAT over 5 years is -$21.4 million, with a median of -$23.5 million recorded in 2022.
- Peak annual rise in EBIAT hit 1211.86% in 2021, while the deepest fall reached 895.78% in 2021.
- Year by year, EBIAT stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then soared by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then surged by 35.52% to -$9.9 million in 2025.
- Business Quant data shows EBIAT for NEO at -$9.9 million in Q4 2025, -$27.1 million in Q3 2025, and -$45.1 million in Q2 2025.